Company / Working Capital
Celldex Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$483.7M
FY2025
5-year range
$299.1M / $707.7M
FY2021-FY2025
Trend
-31.7%
vs FY2024
Sector context
#64 of 160
Health Care
What the data says
At $484M, Celldex Therapeutics, Inc.'s working capital ranks #64 of 160 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $55M in FY2019 to $708M in FY2024.
Based on SEC 10-K filings.
$484M in FY2025 with a 5-year CAGR of +21.4%.
Improved from $401M to $484M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- +21.4%
- 10-Year CAGR
- -
Sector benchmark
#64 of 160 in Health CareTop 40% of 160This company $483.7M Sector average $757.1M
▼
-36.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.4%, indicating consistent growth.
- In FY2025, working capital decreased 31.7% year-over-year.
- Ranks #64 out of 160 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $483.7M | -31.7% |
| FY2024 | $707.7M | +76.7% |
| FY2023 | $400.6M | +33.9% |
| FY2022 | $299.1M | -24.2% |
| FY2021 | $394.3M | +114.7% |
| FY2020 | $183.6M | +233.6% |
| FY2019 | $55.1M | -36.3% |
| FY2018 | $86.5M | -26.1% |
| FY2017 | $117.0M | -27.0% |
| FY2016 | $160.3M | -39.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026